Suppr超能文献

维拉帕米和群多普利对自发性高血压大鼠动脉结构改变的预防作用及其对力学性能的影响

Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats.

作者信息

Koffi I, Lacolley P, Kirchengaast M, Pomiès J P, Laurent S, Benetos A

机构信息

Institut National de la Santé et de la Recherche Médicale, U337, Paris, France.

出版信息

Eur J Pharmacol. 1998 Nov 13;361(1):51-60. doi: 10.1016/s0014-2999(98)00691-8.

Abstract

We compared the chronic effects in spontaneously hypertensive rats (SHR) of low doses of an angiotensin converting enzyme inhibitor, trandolapril, a Ca2+ channel antagonist, verapamil, and their combination (trandolapril-verapamil), on arterial mechanical properties, arterial wall hypertrophy and extracellular matrix proteins. Four-week-old SHR were randomly allocated to oral treatment with verapamil (50 mg kg(-1) day(-1)), trandolapril (0.3 mg kg(-1) day(-1)), the combination of verapamil (50 mg kg(-1) day(-1)) plus trandolapril (0.3 mg kg(-1) day(-1)), or placebo for 4 months. A group of Wistar Kyoto (WKY) control rats received placebo for the same period of time. At the end of the treatment, mean blood pressure was lower in verapamil-trandolapril than in trandolapril SHR, but remained higher than in WKY. Verapamil had no effects on blood pressure. Equivalent reduction in aortic wall hypertrophy was obtained in all treated SHR. Trandolapril and verapamil-trandolapril combination produced a significant reduction of aortic collagen density compared with placebo SHR. Carotid total fibronectin, EIIIA fibronectin isoform and alpha5beta1 integrin, were higher in the media of placebo SHR than in WKY. EIIIA fibronectin isoform and alpha5beta1 integrin were reduced in verapamil-SHR compared with placebo-SHR and normalized in trandolapril and verapamil-trandolapril-SHR compared with WKY. SHR-placebo and SHR treated with either verapamil or trandolapril as single-drug treatment showed a 4-fold increase in total fibronectin compared to the WKY. Only SHR treated with verapamil-trandolapril combination had total fibronectin not significantly different from that of WKY. Carotid arterial distensibility increased only in verapamil-trandolapril treated rats. Multivariate analysis showed arterial distensibility to be negatively correlated to mean blood pressure (P < 0.0001) and total fibronectin (P < 0.01). In conclusion, chronic treatment with the verapamil-trandolapril combination significantly improved in vivo arterial distensibility in SHR. The most important effects of the combination on arterial mechanics compared to those of verapamil or trandolapril alone may have been the consequence of its stronger action on arterial pressure, arterial wall hypertrophy and total fibronectin density. However we suggest that, in addition to the structural effects, complete normalization of blood pressure is necessary to obtain normal arterial distensibility.

摘要

我们比较了低剂量血管紧张素转换酶抑制剂群多普利、钙通道拮抗剂维拉帕米及其组合(群多普利 - 维拉帕米)对自发性高血压大鼠(SHR)动脉力学特性、动脉壁肥厚和细胞外基质蛋白的慢性影响。将四周龄的SHR随机分为四组,分别口服维拉帕米(50毫克/千克/天)、群多普利(0.3毫克/千克/天)、维拉帕米(50毫克/千克/天)加群多普利(0.3毫克/千克/天)的组合或安慰剂,持续4个月。一组Wistar Kyoto(WKY)对照大鼠在同一时期接受安慰剂。治疗结束时,群多普利 - 维拉帕米组的平均血压低于群多普利组的SHR,但仍高于WKY组。维拉帕米对血压无影响。所有治疗的SHR主动脉壁肥厚均有同等程度的减轻。与安慰剂组SHR相比,群多普利和群多普利 - 维拉帕米组合显著降低了主动脉胶原密度。安慰剂组SHR中膜的颈动脉总纤连蛋白、EIIIA纤连蛋白异构体和α5β1整合素高于WKY组。与安慰剂组SHR相比,维拉帕米组SHR的EIIIA纤连蛋白异构体和α5β1整合素减少,与WKY组相比,群多普利组和群多普利 - 维拉帕米组SHR中的这些指标恢复正常。与WKY组相比,SHR -安慰剂组以及单独用维拉帕米或群多普利治疗的SHR组的总纤连蛋白增加了4倍。只有用群多普利 - 维拉帕米组合治疗的SHR组的总纤连蛋白与WKY组无显著差异。仅在群多普利 - 维拉帕米治疗的大鼠中颈动脉扩张性增加。多变量分析显示动脉扩张性与平均血压(P < 0.)和总纤连蛋白(P < 0.01)呈负相关。总之,群多普利 - 维拉帕米组合的慢性治疗显著改善了SHR的体内动脉扩张性。与单独使用维拉帕米或群多普利相比,该组合对动脉力学的最重要影响可能是其对动脉血压、动脉壁肥厚和总纤连蛋白密度的更强作用的结果。然而,我们认为,除了结构效应外,血压完全正常化对于获得正常的动脉扩张性也是必要的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验